Kayvan Keyhani, MD
Ophthalmology · Yorktown Heights, NYNPI 1275549552
Payments from drug & device makers
Across 350 payments — averaging $37.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$4K
- Alcon$2K
- Bausch & Lomb Americas Inc.$854
- Sun Pharmaceutical Industries Inc.$647
- Mallinckrodt Hospital Products Inc.$628
- Glaukos Corporation$561
- plus $4K from 24 others
What the payments were for
- Speaking & faculty fees$1,74113%
- Food & beverage$11,27487%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 12 | $4,334 |
| Alcon | 62 | $1,561 |
| Bausch & Lomb Americas Inc. | 34 | $854 |
| Sun Pharmaceutical Industries Inc. | 26 | $647 |
| Mallinckrodt Hospital Products Inc. | 20 | $628 |
| Glaukos Corporation | 10 | $561 |
| AbbVie(2 entities) | 30 | $503 |
| Amgen(2 entities) | 24 | $472 |
| Aerie Pharmaceuticals, Inc. | 29 | $471 |
| Oyster Point Pharma, Inc. | 14 | $418 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $359 |
| Rxsight Inc | 5 | $339 |
| Tarsus Pharmaceuticals, Inc. | 6 | $258 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $249 |
| Coopervision Inc. | 1 | $241 |
| Novartis | 11 | $219 |
| Sight Sciences, Inc. | 8 | $189 |
| Kala Pharmaceuticals, Inc. | 7 | $134 |
| Eyevance Pharmaceuticals LLC | 6 | $120 |
| Dompe US, Inc. | 5 | $96 |
| Astellas Pharma US Inc | 3 | $65 |
| Biotissue Holdings Inc. | 3 | $61 |
| Mallinckrodt Enterprises LLC | 3 | $57 |
| Harrow Eye, LLC | 2 | $43 |
| Shire North American Group Inc | 2 | $42 |
| Thea Pharma Inc. | 2 | $35 |
| Ivantis, Inc | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$1,855
- Kahook Dual Blade$1,855
- Streamline Surgical System$1,260
- RXSIGHT CONTACT LENS$290
- RXSIGHT INJECTOR CARTRIDGE$290
- RXSIGHT INJECTOR HANDPIECE$290
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$290
- ACTHAR$247
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$156
- AcrySof IQ VIVITY IOL$151
- iStent inject W$150
- Clareon$141
- TYRVAYA$137
- Tecnis IOL$134
- LIGHT ADJUSTABLE LENS (LAL)$134
- enVista MX60 IOL$131
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
- CEQUA$125
- MIEBO$120
How this compares
$13,023 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 329 | $113,185 |
| RestasisCyclosporine | 31 | $48,296 |
| Prednisolone Acetate | 757 | $37,558 |
| Gatifloxacin | 570 | $23,255 |
| XiidraLifitegrast | 18 | $21,495 |
| VyzultaLatanoprostene Bunod | 30 | $19,464 |
| Bromfenac Sodium | 63 | $11,291 |
| CequaCyclosporine | 12 | $9,103 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $8,696 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $6,272 |
| Latanoprost | 265 | $3,479 |
| Ofloxacin | 132 | $1,529 |
| Fluorometholone | 19 | $1,377 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $1,115 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 22 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $249 | $113,185329 claims |
| AbbVieRestasis, Combigan | $503 | $56,99246 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $854 | $40,95948 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $647 | $9,10312 claims |
| AlconSimbrinza | $1,561 | $6,27225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Yorktown Heights
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.